Impact of Anti-CMV IgG Titers and CD34 Count Prior to Hematopoietic Stem Cell Transplantation from Alternative Donors on CMV reactivation

Leonardo Javier Arcuri , Marcelo Schirmer , Marta Colares , Simone Maradei , Rita Tavares , Maria Claudia Rodrigues Moreira , Renato de Castro Araujo , Decio Lerner , Antonio Guilherme Fonseca Pacheco
{"title":"Impact of Anti-CMV IgG Titers and CD34 Count Prior to Hematopoietic Stem Cell Transplantation from Alternative Donors on CMV reactivation","authors":"Leonardo Javier Arcuri ,&nbsp;Marcelo Schirmer ,&nbsp;Marta Colares ,&nbsp;Simone Maradei ,&nbsp;Rita Tavares ,&nbsp;Maria Claudia Rodrigues Moreira ,&nbsp;Renato de Castro Araujo ,&nbsp;Decio Lerner ,&nbsp;Antonio Guilherme Fonseca Pacheco","doi":"10.1016/j.bbmt.2020.07.034","DOIUrl":null,"url":null,"abstract":"<div><p>Cytomegalovirus (CMV) reactivation remains one of the main infectious complications following hematopoietic stem cell transplantation (HSCT). In this study, we explored the role of anti-CMV antibody titers in HSCT from alternative donors and to compare the risk of CMV reactivation between posttransplant cyclophosphamide-based haploidentical HSCT and antithymocyte globulin-based unrelated donor (URD) HSCT. We included 98 CMV-positive patients, 30 undergoing haploidentical HSCT and 68 undergoing URD HSCT. The majority of patients had a malignant disease (84%), received a myeloablative conditioning regimen (78%), and received a bone marrow graft (90%). The median pretransplantation anti-CMV IgG level was 109 U/mL. With median follow-up of 2.2 years, a total of 72 CMV reactivations occurred in 50 patients. There was no difference in CMV reactivation pattern between haploidentical HSCT recipients and URD HSCT recipients. In multivariable analysis until the first event, the incidence of CMV reactivation was higher in patients with anti-CMV IgG levels &gt;100 U/mL (hazard ratio [HR], 2.38; <em>P</em> = .005) and in patients diagnosed with grade II-IV acute graft-versus-host disease (GVHD) (HR, 10.8; <em>P</em> = .003) after day +50 and lower in patients who received higher doses of CD34 cells (HR, .44; <em>P</em> = .006). In multivariable analysis for recurring events, the incidence of CMV reactivation was higher in patients receiving reduced-intensity conditioning (HR, 1.69: <em>P</em> = .04) and in patients with acute GVHD (HR, 1.88; <em>P</em> = .02), and lower in those who received higher doses of CD34 cells (HR, .55; <em>P</em> = .01). In summary, we have shown that pretransplantation anti-CMV IgG titers are correlated with CMV reactivation risk. More studies are needed to assess how this information can be incorporated in HSCT. The use of high-dose cellular grafts, a modifiable risk factor, also protects against CMV reactivation.</p></div>","PeriodicalId":9165,"journal":{"name":"Biology of Blood and Marrow Transplantation","volume":null,"pages":null},"PeriodicalIF":4.3000,"publicationDate":"2020-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.bbmt.2020.07.034","citationCount":"10","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Biology of Blood and Marrow Transplantation","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1083879120304663","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 10

Abstract

Cytomegalovirus (CMV) reactivation remains one of the main infectious complications following hematopoietic stem cell transplantation (HSCT). In this study, we explored the role of anti-CMV antibody titers in HSCT from alternative donors and to compare the risk of CMV reactivation between posttransplant cyclophosphamide-based haploidentical HSCT and antithymocyte globulin-based unrelated donor (URD) HSCT. We included 98 CMV-positive patients, 30 undergoing haploidentical HSCT and 68 undergoing URD HSCT. The majority of patients had a malignant disease (84%), received a myeloablative conditioning regimen (78%), and received a bone marrow graft (90%). The median pretransplantation anti-CMV IgG level was 109 U/mL. With median follow-up of 2.2 years, a total of 72 CMV reactivations occurred in 50 patients. There was no difference in CMV reactivation pattern between haploidentical HSCT recipients and URD HSCT recipients. In multivariable analysis until the first event, the incidence of CMV reactivation was higher in patients with anti-CMV IgG levels >100 U/mL (hazard ratio [HR], 2.38; P = .005) and in patients diagnosed with grade II-IV acute graft-versus-host disease (GVHD) (HR, 10.8; P = .003) after day +50 and lower in patients who received higher doses of CD34 cells (HR, .44; P = .006). In multivariable analysis for recurring events, the incidence of CMV reactivation was higher in patients receiving reduced-intensity conditioning (HR, 1.69: P = .04) and in patients with acute GVHD (HR, 1.88; P = .02), and lower in those who received higher doses of CD34 cells (HR, .55; P = .01). In summary, we have shown that pretransplantation anti-CMV IgG titers are correlated with CMV reactivation risk. More studies are needed to assess how this information can be incorporated in HSCT. The use of high-dose cellular grafts, a modifiable risk factor, also protects against CMV reactivation.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
替代供者造血干细胞移植前抗巨细胞病毒IgG滴度和CD34计数对巨细胞病毒再激活的影响
巨细胞病毒(CMV)再激活仍然是造血干细胞移植(HSCT)后主要的感染性并发症之一。在这项研究中,我们探讨了抗巨细胞病毒抗体滴度在替代供体HSCT中的作用,并比较了移植后基于环磷酰胺的单倍体HSCT和基于抗胸腺细胞球蛋白的非相关供体(URD) HSCT中巨细胞病毒再激活的风险。我们纳入了98例cmv阳性患者,其中30例接受单倍体HSCT, 68例接受URD HSCT。大多数患者患有恶性疾病(84%),接受清骨髓调理方案(78%),并接受骨髓移植(90%)。移植前抗巨细胞病毒IgG水平中位数为109 U/mL。中位随访时间为2.2年,50例患者共发生72例巨细胞病毒再激活。单倍体HSCT受者和非单倍体HSCT受者的巨细胞病毒再激活模式没有差异。在第一次事件发生前的多变量分析中,抗巨细胞病毒IgG水平为100 U/mL的患者巨细胞病毒再激活的发生率更高(风险比[HR], 2.38;P = 0.005)和诊断为II-IV级急性移植物抗宿主病(GVHD)的患者(HR, 10.8;P = 0.003),而接受高剂量CD34细胞的患者在第50天后的死亡率更低(HR, 0.44;p = .006)。在对复发事件的多变量分析中,CMV再激活的发生率在接受低强度调节的患者(HR, 1.69: P = 0.04)和急性GVHD患者(HR, 1.88;P = .02),而接受高剂量CD34细胞的患者死亡率更低(HR, .55;p = 0.01)。总之,我们已经证明移植前抗巨细胞病毒IgG滴度与巨细胞病毒再激活风险相关。需要更多的研究来评估如何将这些信息纳入HSCT。使用高剂量的细胞移植物,一个可改变的危险因素,也可以防止巨细胞病毒再激活。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
6.60
自引率
0.00%
发文量
1061
审稿时长
3-6 weeks
期刊介绍: Biology of Blood and Marrow Transplantation publishes original research reports, reviews, editorials, commentaries, letters to the editor, and hypotheses and is the official publication of the American Society for Transplantation and Cellular Therapy. The journal focuses on current technology and knowledge in the interdisciplinary field of hematopoetic stem cell transplantation.
期刊最新文献
Table of Contents Editorial Board Goal-Oriented Monitoring of Cyclosporine Is Effective for Graft-versus-Host Disease Prevention after Hematopoietic Stem Cell Transplantation in Sickle Cell Disease and Thalassemia Major Early Mixed Lymphoid Donor/Host Chimerism is Associated with Improved Transplant Outcome in Patients with Primary or Secondary Myelofibrosis Real-World Issues and Potential Solutions in Hematopoietic Cell Transplantation during the COVID-19 Pandemic: Perspectives from the Worldwide Network for Blood and Marrow Transplantation and Center for International Blood and Marrow Transplant Research Health Services and International Studies Committee
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1